- Additional research centers now enrolling patients in Australia and New Zealand - Company has achieved 50 percent of target enrollment in global Phase 3 trial LONDON
Clinical research facilities in NZ have been taking on more trials as other facilities around the world grapple with ongoing Covid-19 outbreaks and lockdowns.
First Positive Data of In Vivo CRISPR-Based Genome Editing in Humans Reported
June 28, 2021
A team of researchers based in the U.S., the U.K., and New Zealand from Intellia Therapeutics, Regeneron Pharmaceuticals, and clinical partners showed in a study that the companies’ lead
in vivo genome editing candidate NTLA-2001 generated a dose-dependent sustained reduction of protein linked to transthyretin (ATTR) amyloidosis following a single dose in six patients living with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
The study is the first ever to support the safety and efficacy of
in vivo CRISPR genome editing in humans.
The New England Journal of Medicine and in a presentation that day at the 2021 Peripheral Nerve Society (PNS) Annual Meeting the researchers reported that a single 0.3 mg/kg dose of NTLA-2001 led to an 87% mean reduction in serum transthyretin (TTR) protein concentration in three of the ATTRv-PN patients by day 28, with individual re